Last update 21 Nov 2024
Atorvastatin Calcium Hydrate/Torcetrapib
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Atorvastatin/torcetrapib, Torcetrapib/atorvastatin |
Mechanism CETP inhibitors(Cholesteryl ester transfer protein inhibitors), HDL-cholesterol stimulants, HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC33H35CaFN2O5 |
InChIKeyBWFCZHDTTAYGNN-CNZCJKERSA-N |
CAS Registry134523-03-8 |
View All Structures (3)
Related
14
Clinical Trials associated with Atorvastatin Calcium Hydrate/TorcetrapibA Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030)
Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia.
A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031)
100 Clinical Results associated with Atorvastatin Calcium Hydrate/Torcetrapib
Login to view more data
100 Translational Medicine associated with Atorvastatin Calcium Hydrate/Torcetrapib
Login to view more data
100 Patents (Medical) associated with Atorvastatin Calcium Hydrate/Torcetrapib
Login to view more data
100 Deals associated with Atorvastatin Calcium Hydrate/Torcetrapib
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Heterozygous familial hypercholesterolemia | Phase 3 | AU | 01 Mar 2005 | |
| Heterozygous familial hypercholesterolemia | Phase 3 | NO | 01 Mar 2005 | |
| Heterozygous familial hypercholesterolemia | Phase 3 | CA | 01 Mar 2005 | |
| Heterozygous familial hypercholesterolemia | Phase 3 | DK | 01 Mar 2005 | |
| Hyperlipoproteinemia Type IV | Phase 3 | US | 01 Feb 2005 | |
| Hyperlipoproteinemia Type IV | Phase 3 | CA | 01 Feb 2005 | |
| Coronary Disease | Phase 3 | US | 01 Oct 2003 | |
| Coronary Disease | Phase 3 | NL | 01 Oct 2003 | |
| Coronary Disease | Phase 3 | CA | 01 Oct 2003 | |
| Coronary Disease | Phase 3 | ES | 01 Oct 2003 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free